Nurix Therapeutics (NRIX) Net Margin (2019 - 2026)
Nurix Therapeutics (NRIX) posted quarterly Net Margin of 990.1% for Q2 2026, down 89145.0% year-over-year from N/an in Q2 2025, and up 29.62% quarter-over-quarter from 1406.73% in Q1 2026.
Powered by 
Analysis
Nurix Therapeutics (NRIX) Net Margin (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has reported Net Margin for 8 consecutive years, with 990.1% the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Margin fell 89145.0% year-over-year to 990.1%; the TTM figure through May 2026 stood at 930.55% (down 69597.0% YoY), while the FY2025 annual figure was 314.9%, up 3995.0% from the prior year.
- Net Margin grew to 990.1% in Q2 2026 per NRIX's latest filing, from 1406.73% in the prior quarter.
- Across five years, Net Margin topped out at 79.14% in Q2 2023 and bottomed at 1406.73% in Q1 2026.
- Historically, Net Margin has averaged 486.05% across 5 years, with a median of 393.02% in 2022.
- Annual changes were most pronounced in 2023 — Net Margin surged 41196 bps — and 2026, when it sank 110136 bps.
- Nurix Therapeutics' Net Margin stood at 688.74% in 2022, then surged by 60 bps to 276.77% in 2023, then sank by 59 bps to 440.75% in 2024, then sank by 31 bps to 576.13% in 2025, then tumbled by 72 bps to 990.1% in 2026.
- Business Quant data shows NRIX's Net Margin at 990.1% in Q2 2026, 1406.73% in Q1 2026, and 576.13% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Nurix Therapeutics | 2.90 Bn | 2.46 Bn | - | -990.10% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | -990.10% |
| Feb 28, 2026 | -1,394.34% |
| Nov 30, 2025 | -576.13% |
| Aug 31, 2025 | -1,094.77% |
| May 31, 2025 | -98.66% |
| Feb 28, 2025 | -305.38% |
| Nov 30, 2024 | -440.75% |
| Aug 31, 2024 | -388.91% |
| May 31, 2024 | -368.39% |
| Feb 29, 2024 | -250.33% |
| Nov 30, 2023 | -276.77% |
| Aug 31, 2023 | -200.26% |
| May 31, 2023 | -79.14% |
| Feb 28, 2023 | -321.11% |
| Nov 30, 2022 | -688.74% |
| Aug 31, 2022 | -423.58% |
| May 31, 2022 | -397.14% |
| Feb 28, 2022 | -442.09% |
| Nov 30, 2021 | -509.59% |
| Aug 31, 2021 | -281.26% |